Trifluoroacetyl‐effect on amino‐single benzene‐based fluorophores: Synthesis, optical properties, and cytotoxicity
作者:Ji Hye Jin、Dopil Kim、Jisoo Kang、Sangho Lee、Jong Min An、Min Kim、Dokyoung Kim
DOI:10.1002/bkcs.12836
日期:——
Amino-single benzene-based fluorophores (SBBFs) are representative small-size fluorescent dyes that have an electron push-pull structure within the benzene core. In this work, a new library of amino-SBBFs, which have trifluoroacetyl moiety at the electron-pushing amine group (named SBBF-TFA), featuring a variety of methylamines, dimethylamines, as well as acetyl. To explore the SBBF-TFA library, we
氨基单苯基荧光团(SBBF)是具有代表性的小尺寸荧光染料,其苯核内具有电子推拉结构。在这项工作中,我们建立了一个新的氨基-SBBF库,其在电子推动胺基团上具有三氟乙酰基部分(称为SBBF-TFA),具有多种甲胺、二甲胺以及乙酰基。为了探索 SBBF-TFA 库,我们进行了 (i) 库合成,(ii) 评估九种不同类型的有机/水溶剂中的各种光物理性质,以及 (iii) 评估 HeLa 细胞系的细胞毒性。我们相信,我们的研究结果为推进新型小分子荧光探针和材料在药物化学领域的多种应用提供了宝贵的见解。
PROLYL HYDROXYLASE INHIBITORS
申请人:GlaxoSmithKline LLC
公开号:EP2240178A1
公开(公告)日:2010-10-20
[EN] PROLYL HYDROXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE PROLYLHYDROXYLASE
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2009086044A1
公开(公告)日:2009-07-09
The invention described herein relates to certain 4-oxo-2-thioxo- 1,2,3, 4-tetrahydro-7-quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
[EN] PROLYL HYDROXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROLYL HYDROXYLASE
申请人:GLAXOSMITHKLINE LLC
公开号:WO2010059549A1
公开(公告)日:2010-05-27
The invention described herein relates to certain 2,4-dioxo-l,2,3,4-tetrahydro-7- quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
The invention described herein relates to certain 4-oxo-2-thioxo-1,2,3,4-tetrahydro-7-quinazolinecarboxamide derivatives of formula (I)
which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.